AT HOME DRUG TEST, MODEL 9171

K991824 · Phamatech · MVO · Jun 11, 1999 · TX

Device Facts

• Record ID: K991824
• Device Name: AT HOME DRUG TEST, MODEL 9171
• Applicant: Phamatech
• Product Code: MVO · TX
• Decision Date: Jun 11, 1999
• Decision: SESE
• Submission Type: Special
• Device Class: Class U

Intended Use

The At Home Drug Test is a rapid, qualitative immunoassay for the detection of the target drugs/drug metabolites in urine. The cut-off concentration for these test is as follows: methamphetamine; 500 ng/ml and opiates; 300 ng/ml. This assay is intended for use in the home to assist in the prevention of drug abuse. This kit is designed to incorporate a mechanism for anonymous confirmation testing to be performed at a certified laboratory.

Device Story

At Home Drug Test (Model 9171) is a lateral flow, one-step, qualitative immunoassay for urine drug screening. Device utilizes immunochemical sandwich assay principle; specific antibodies bind to target drugs/metabolites (methamphetamine, opiates) to produce visual color change. Intended for home use by lay users to assist in drug abuse prevention. Kit includes mechanism for anonymous laboratory confirmation. Output is visual qualitative result (presence/absence of drug above specified cut-offs). Provides preliminary screening; positive results require laboratory confirmation via GC/MS or similar methods. Benefits include accessible, rapid, private preliminary testing for consumers.

Clinical Evidence

Clinical sample correlation study and blind labeled spiked study performed. Correlations with Behring EMIT II and GC/MS methodology showed >98% correlation. Clinical studies at two independent labs showed >97% accuracy for professional users. Consumer study showed >96.4% accuracy for lay users.

Technological Characteristics

Lateral flow, one-step, visual color sandwich immunoassay. Qualitative detection of methamphetamine (500 ng/ml cut-off) and opiates (300 ng/ml cut-off) in urine. Standalone, non-electronic, disposable test kit.

Indications for Use

Indicated for home drug screening and confirmation service for the preliminary detection of methamphetamine and opiates in human urine.

Predicate Devices

• QuickScreen At Home Drug Test
• Applied Biotech SureStep Test

Reference Devices

• Behring EMIT II

Submission Summary (Full Text)

{0}------------------------------------------------

JUN 11 1999

## 510 (k) SUMMARY AS REQUIRED BY SECTION 807.92(C)

At Home Drug Test (Model 9171) Identification:

Description: Immunoassay for the qualitative detection Methamphetamine and Opiate in urine

Name Of Manufacturer:

Phamatech 9265 Activity Road #112 San Diego, California 92126, USA

Intended Use: The At Home Drug Test is a rapid, qualitative immunoassay for the detection of the target drugs/drug metabolites in urine. The cut-off concentration for these test is as follows: methamphetamine; 500 ng/ml and opiates; 300 ng/ml. This assay is intended for use in the home to assist in the prevention of drug abuse. This kit is designed to incorporate a mechanism for anonymous confirmation testing to be performed at a certified laboratory.

The At Home Drug Test, like many commercially available drug screening Technology: test kits, qualitatively measures the presence of target drugs or their metabolites by visual color sandwich one step immunoassay technology. Examples of such predicate devices include the QuickScreen At Home Drug Test and the Applied Biotech SureStep Test (San Diego, CA 92121). All of the above devices rely on the basic immunochemical sandwich assay principle of recognition and formation of specific antibody / target drug / antibody / complexes.

Performance: The product performance characteristics of the At Home Drug Test were evaluated in a clinical sample correlation study and a blind labeled spiked study. The results of these studies demonstrate the Phamatech At Home Drug Test to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of the stated target drugs in urine. Correlations studies, using clinical specimens, produced a >98% correlation when compared to the Behring EMIT II (Cupertino, CA 95014) and GC/MS methodology. Clinical studies, performed at two independent laboratories, were also performed. In them the Phamatech QuickScreen™ exhibited excellent overall accuracy (>97%) in the hands of professional users. A comsumer study was also performed. In it the At Home Drug Test exhibited excellent overall accuracy (>96.4%) in the hands of lay users.

Conclusion: For the reasons mentioned above, it may be concluded that the Phamatech At Home Drug Test is substantially equivalent to a variety of detection tests currently in commercial distribution and is safe in the hands of the lay user.

{1}------------------------------------------------

Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three curved lines.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

JUN 11 1999

Mr. Carl A. Mongiovi Vice President of Operations Phamatech 9265 Activity Road #112 San Diego, California 92126

Re: K991824

Trade Name: OuickScreen At Home Drug Test Model 9171 Regulatory Class: II Product Code: MVO Dated: May 25, 1999 Received: May 27, 1999

Dear Mr. Mongiovi:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{2}------------------------------------------------

## Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at [phone].

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone], or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Putman

Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

## INDICATIONS FOR USE

Applicant: Phamatech

510 (k) Number (if known): _K 99 lな24

Device Name: At Home Drug Test (Model 9171)

Indications for Use:

A home drug screening, and if needed, confirmation service. This kit provides a preliminary result for the detection/presence of the following drugs of abuse in urine: Methamphetamine and Opiates

## PLEASE DO NOT WRITE BELOW THIS LINE

Concurrence of the CDRH Office of Device Evaluation (ODE)

signature

Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number_K 991824

Division Sign-off Division of Clinical Laboratory Devices 2 x 1000 510 (k) Number: Prescription Use: OR Over the Counter: v Per 21 CFR 801.109